The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00884494
: April 20, 2009
Last Update Posted
: January 20, 2017
Vanderbilt University Medical Center
Information provided by (Responsible Party):
Robyn Tamboli, Vanderbilt University Medical Center
Ghrelin, a hormone produced in the stomach that stimulates hunger and food intake, declines immediately after weight loss surgery. Some studies suggest that ghrelin may worsen an individual's ability to respond to insulin. The purpose of this study is to determine if the decline in ghrelin levels after weight loss surgery contributes to the improvement of insulin sensitivity.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 65 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Inclusion Criteria for RYGB group:
BMI > 35 kg/m2
Scheduled for bariatric surgery at Vanderbilt University Medical Center
Inclusion Criteria for Lean group:
BMI < 30kg/m2
Prior bariatric surgery
Serum creatinine > 1.5 mg/dl
Hepatic enzyme elevations > 2x upper limits of normal